Literature DB >> 434075

Patient compliance with use of topical ophthalmic corticosteroid suspensions.

L Apt, A Henrick, L M Silverman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 434075     DOI： 10.1016/0002-9394(79)90145-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  7 in total

Review 1.  Clinical pharmacokinetics of various topical ophthalmic delivery systems.

Authors:  J P Frangie
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

Review 2.  Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

3.  Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%.

Authors:  William Stringer; Roy Bryant
Journal:  Clin Ophthalmol       Date:  2010-10-05

4.  Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop.

Authors:  Martin J Coffey; Heleen H Decory; Stephen S Lane
Journal:  Clin Ophthalmol       Date:  2013-02-13

5.  Difluprednate for the prevention of ocular inflammation postsurgery: an update.

Authors:  Eric D Donnenfeld
Journal:  Clin Ophthalmol       Date:  2011-06-15

6.  Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%).

Authors:  Zora T Marlowe; Stephen R Davio
Journal:  Clin Ophthalmol       Date:  2013-12-10

7.  Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1.

Authors:  Zora T Marlowe; Megan E Cavet; Martin J Coffey
Journal:  Ophthalmol Ther       Date:  2021-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.